Abstract：【Objective】To investigate the effect of intravesical perfusion of mitomycin after transurethral resection of non-muscle invasive bladder cancer (TURBt).【Methods】A total of 86 patients with non-muscle invasive bladder cancer were divided into the control group (43 cases, underwent TURBt ) and the observation group (43 cases, underwent TURBt and combined with mitomycin for bladder infusion). The differences in postoperative recurrence rate, serum tumor related factors, adverse reactions and quality of life were compared between the two groups.【Results】The recurrence rate of the observation group was significantly lower that of the control group (P<0.05). The average recurrence time was significantly longer than that of the control group (P<0.05). The serum levels of VEGF, FGF and MMP-9 in the observation group were significantly lower than those in the control group (P<0.05). The incidence of bladder irritation in the observation group was higher than that in the control group (P<0.05), while the incidence of adverse reactions such as nausea and vomiting, chest tightness and palpitations did not show statistically significant difference (P>0.05). The EORTC QLQ-C30 score and KPS score of the two groups were higher than those before operation (P<0.05), and the two scores in the observation group were significantly higher than those in the control group (P<0.05).【Conclusion】TURBt combined with early mitomycin-induced bladder perfusion therapy on non-muscle infiltration bladder cancer can reduce the recurrence rate, improve the serum levels of tumor related factors without obvious adverse reactions, and improve the quality of life of patients. It is worthy of clinical promotion.
2019, Vol. 36 
